Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
Orna Therapeutics, a biotech working on circular RNA with a new twist on CAR therapies, has laid off employees, CEO Tom Barnes confirmed to Endpoints News.
First, to the Merck deal. The Big Pharma is making the upfront payment and committing to up to $3.5 billion in milestones to work with Orna to advance programs including engineered circular RNA (oRNA) vaccines and therapeutics against infectious diseases and cancers. Orna will retain rights to its oRNA-LNP platform and continue to advance other wholly owned programs internally.